Steris (NYSE:STE) has been assigned a $102.00 price target by stock analysts at Northcoast Research in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Northcoast Research’s target price points to a potential upside of 18.76% from the stock’s current price.
A number of other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Steris from a “buy” rating to a “hold” rating in a report on Wednesday, January 24th. Raymond James Financial reiterated a “market perform” rating and issued a $100.00 price target on shares of Steris in a report on Wednesday, January 3rd. TD Securities lifted their price target on shares of Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Finally, KeyCorp reiterated an “overweight” rating and issued a $101.00 price target (up previously from $91.00) on shares of Steris in a report on Thursday, November 2nd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $84.40.
Shares of Steris (STE) traded down $0.28 on Thursday, hitting $85.89. 424,578 shares of the company’s stock were exchanged, compared to its average volume of 377,873. The firm has a market cap of $7,290.00, a price-to-earnings ratio of 30.43 and a beta of 1.22. Steris has a 52 week low of $66.36 and a 52 week high of $93.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.18 and a current ratio of 2.80.
In related news, VP Sudhir K. Pahwa sold 2,000 shares of Steris stock in a transaction on Monday, January 29th. The shares were sold at an average price of $92.09, for a total transaction of $184,180.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP John Adam Zangerle sold 3,650 shares of Steris stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total transaction of $321,200.00. The disclosure for this sale can be found here. Insiders own 2.55% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. New Mexico Educational Retirement Board acquired a new position in shares of Steris during the 4th quarter valued at $1,838,000. Swiss National Bank lifted its holdings in shares of Steris by 1.8% during the 4th quarter. Swiss National Bank now owns 144,855 shares of the medical equipment provider’s stock valued at $12,670,000 after acquiring an additional 2,600 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of Steris by 106.7% during the 4th quarter. Daiwa Securities Group Inc. now owns 196,421 shares of the medical equipment provider’s stock valued at $17,181,000 after acquiring an additional 101,396 shares in the last quarter. California Public Employees Retirement System lifted its holdings in shares of Steris by 5.6% during the 4th quarter. California Public Employees Retirement System now owns 223,243 shares of the medical equipment provider’s stock valued at $19,527,000 after acquiring an additional 11,899 shares in the last quarter. Finally, M&T Bank Corp lifted its holdings in shares of Steris by 15.2% during the 4th quarter. M&T Bank Corp now owns 14,764 shares of the medical equipment provider’s stock valued at $1,292,000 after acquiring an additional 1,952 shares in the last quarter. Institutional investors and hedge funds own 89.63% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/08/steris-ste-given-a-102-00-price-target-at-northcoast-research.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.